{"id":"https://openalex.org/W2007844082","doi":"https://doi.org/10.1177/0091270011407068","title":"A Novel PEGylated Interferon Beta\u20101a for Multiple Sclerosis: Safety, Pharmacology, and Biology","display_name":"A Novel PEGylated Interferon Beta\u20101a for Multiple Sclerosis: Safety, Pharmacology, and Biology","alternate_titles":[],"publication_year":2012,"publication_date":"2012-06-01","ids":{"openalex":"https://openalex.org/W2007844082","doi":"https://doi.org/10.1177/0091270011407068","mag":"2007844082","pmid":"https://pubmed.ncbi.nlm.nih.gov/21680782"},"language":"en","primary_location":{"id":"doi:10.1177/0091270011407068","doi":"https://doi.org/10.1177/0091270011407068","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270011407068","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2007844082"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102962652","display_name":"Xiao Shelley Hu","orcid":"https://orcid.org/0000-0002-7387-7730","observed_orcids":["https://orcid.org/0000-0002-7387-7730"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Xiao Hu","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts, USA. xiao.hu@biogenidec.com","Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts, USA. xiao.hu@biogenidec.com","institution_ids":["https://openalex.org/I1297540436"]},{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072650322","display_name":"Larisa Miller","orcid":"https://orcid.org/0000-0003-4555-8123","observed_orcids":["https://orcid.org/0000-0003-4555-8123"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Larisa Miller","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028240490","display_name":"Sandra Richman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sandra Richman","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026477546","display_name":"Stacy Hitchman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stacy Hitchman","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040423986","display_name":"Gabrielle Glick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gabrielle Glick","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104652552","display_name":"Shifang Liu","orcid":"https://orcid.org/0009-0003-9037-4902","observed_orcids":["https://orcid.org/0009-0003-9037-4902"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shifang Liu","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048449105","display_name":"Ying Zhu","orcid":"https://orcid.org/0000-0001-7188-1990","observed_orcids":["https://orcid.org/0000-0001-7188-1990"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ying Zhu","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005877381","display_name":"Mary Crossman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mary Crossman","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047793319","display_name":"Ivan A. Nestorov","orcid":"https://orcid.org/0000-0002-1834-2792","observed_orcids":["https://orcid.org/0000-0002-1834-2792"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ivan Nestorov","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060442980","display_name":"Robert S. Gronke","orcid":"https://orcid.org/0009-0002-9048-9550","observed_orcids":["https://orcid.org/0009-0002-9048-9550"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert S. Gronke","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105468423","display_name":"Darren P. Baker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Darren P. Baker","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001238100","display_name":"Mark C. Rogge","orcid":"https://orcid.org/0000-0002-7632-5851","observed_orcids":["https://orcid.org/0000-0002-7632-5851"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark Rogge","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079613346","display_name":"Meena Subramanyam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Meena Subramanyam","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033054901","display_name":"Gudarz Davar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gudarz Davar","raw_affiliation_strings":["Biogen Idec, Inc, Weston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Idec, Inc, Weston, Massachusetts","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5102962652"],"corresponding_institution_ids":["https://openalex.org/I1297540436"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":7.7447,"has_fulltext":false,"cited_by_count":129,"citation_normalized_percentile":{"value":0.98033112,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"52","issue":"6","first_page":"798","last_page":"808"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-beta-1a","display_name":"interferon beta-1a","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pegylation","display_name":"PEGylation","score":0.7599999904632568},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.9670000076293945},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9330000281333923},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9570000171661377},{"id":"https://openalex.org/keywords/neopterin","display_name":"neopterin","score":0.9620000123977661},{"id":"https://openalex.org/keywords/lymphocyte-subsets","display_name":"lymphocyte subsets","score":0.9929999709129333},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.8100000023841858},{"id":"https://openalex.org/keywords/flu-like-symptoms","display_name":"flu-like symptoms","score":0.8080000281333923},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.6269999742507935},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.5299999713897705},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.4569999873638153}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7448774576187134},{"id":"https://openalex.org/C2994247566","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta","level":3,"score":0.6725812554359436},{"id":"https://openalex.org/C2776461080","wikidata":"https://www.wikidata.org/wiki/Q7160835","display_name":"Pegylated interferon","level":5,"score":0.6269062757492065},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5709941983222961},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5435975790023804},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.5240892767906189},{"id":"https://openalex.org/C2776190711","wikidata":"https://www.wikidata.org/wiki/Q7398663","display_name":"Safety pharmacology","level":3,"score":0.5197943449020386},{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.4680808484554291},{"id":"https://openalex.org/C2910198813","wikidata":"https://www.wikidata.org/wiki/Q1851162","display_name":"Interferon beta-1b","level":4,"score":0.44246405363082886},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3608365058898926},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25349122285842896},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.24467292428016663},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.22193819284439087},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.1330428123474121},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.11696934700012207},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.08442497253417969},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.07168993353843689},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001711","descriptor_name":"Biotransformation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005786","descriptor_name":"Gene Expression Regulation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006377","descriptor_name":"T-Lymphocytes, Helper-Inducer","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006377","descriptor_name":"T-Lymphocytes, Helper-Inducer","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007372","descriptor_name":"Interferons","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015088","descriptor_name":"2',5'-Oligoadenylate Synthetase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015088","descriptor_name":"2',5'-Oligoadenylate Synthetase","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015088","descriptor_name":"2',5'-Oligoadenylate Synthetase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D016899","descriptor_name":"Interferon-beta","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D019798","descriptor_name":"Neopterin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D020529","descriptor_name":"Multiple Sclerosis, Relapsing-Remitting","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0091270011407068","doi":"https://doi.org/10.1177/0091270011407068","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0091270011407068","pdf_url":null,"source":{"id":"https://openalex.org/S146237847","display_name":"The Journal of Clinical Pharmacology","issn_l":"0021-9754","issn":["0021-9754","0091-2700","0095-9863","1552-4604","2375-0839","2375-0928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:21680782","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21680782","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":25,"referenced_works":["https://openalex.org/W1578741880","https://openalex.org/W1968010370","https://openalex.org/W1996095106","https://openalex.org/W2009862063","https://openalex.org/W2010080741","https://openalex.org/W2021156693","https://openalex.org/W2024451515","https://openalex.org/W2036364847","https://openalex.org/W2039871617","https://openalex.org/W2054515120","https://openalex.org/W2055559275","https://openalex.org/W2064550759","https://openalex.org/W2064816281","https://openalex.org/W2076341822","https://openalex.org/W2080320061","https://openalex.org/W2088499363","https://openalex.org/W2094375186","https://openalex.org/W2139367012","https://openalex.org/W2141111992","https://openalex.org/W2146029618","https://openalex.org/W2151491950","https://openalex.org/W2165084047","https://openalex.org/W2165547142","https://openalex.org/W2169098250","https://openalex.org/W4210548604"],"related_works":["https://openalex.org/W2147824923","https://openalex.org/W2064550759","https://openalex.org/W3087096460","https://openalex.org/W1703303678","https://openalex.org/W318910913","https://openalex.org/W2980547324","https://openalex.org/W2122290258","https://openalex.org/W4386050922","https://openalex.org/W2487193709","https://openalex.org/W2772313017"],"abstract_inverted_index":{"This":[0],"study":[1,34,59],"clinically":[2],"evaluated":[3],"a":[4,13,32,57,102,176,192],"novel":[5],"PEGylated":[6],"form":[7],"of":[8,114,188],"interferon":[9],"beta-1a":[10,43,53,66,97,116,152,159,190],"(PEG-IFN":[11],"beta-1a),":[12],"potential":[14],"first-line":[15],"treatment":[16,195],"for":[17,196],"relapsing":[18,199],"multiple":[19,200],"sclerosis,":[20],"in":[21,95,128,135,167],"healthy":[22],"volunteers.":[23],"Two":[24],"randomized,":[25],"blinded":[26],"phase":[27],"I":[28],"studies":[29],"were":[30,145,175],"conducted:":[31],"single-dose":[33],"(n":[35,60],"=":[36,61],"60)":[37],"comparing":[38,63],"subcutaneous":[39,64],"or":[40,46,71],"intramuscular":[41,50,123],"PEG-IFN":[42,65,96,115,151,158,189],"(63,":[44],"125,":[45],"188":[47],"\u00b5g)":[48],"with":[49,74,101,118,150,154,163,198],"unmodified":[51,124,155],"IFN":[52,125,156],"30":[54,119],"\u00b5g":[55,108,120],"and":[56,79,83,90,130,133,142,147,170],"multiple-dose":[58],"69)":[62],"dosed":[67],"once":[68],"every":[69],"2":[70],"4":[72],"weeks":[73],"placebo.":[75],"Assessments":[76],"included":[77],"pharmacokinetic":[78],"pharmacodynamic":[80],"(serum":[81],"neopterin":[82,129],"2',5'-OAS)":[84],"measures,":[85],"exploratory":[86],"immune":[87],"assessments,":[88],"safety,":[89],"tolerability.":[91],"A":[92],"dose-proportional":[93],"increase":[94],"exposure":[98,105],"was":[99,160],"observed,":[100],"4-fold":[103],"greater":[104,146],"at":[106],"63":[107],"(6":[109,121],"million":[110],"international":[111],"units":[112],"[MIU])":[113],"than":[117,153],"MIU)":[122],"beta-1a.":[126,157],"Increases":[127],"2',5'-OAS":[131],"levels":[132],"changes":[134],"T":[136],"helper":[137],"cell":[138],"pathway":[139],"gene":[140],"expression":[141],"lymphocyte":[143],"subsets":[144],"more":[148],"sustained":[149],"well":[161],"tolerated,":[162],"only":[164],"transient":[165],"reductions":[166],"absolute":[168],"neutrophils":[169],"some":[171],"lymphocytes.":[172],"Flu-like":[173],"symptoms":[174],"commonly":[177],"reported":[178],"adverse":[179],"event.":[180],"These":[181],"data":[182],"support":[183],"the":[184],"continued":[185],"clinical":[186],"development":[187],"as":[191],"potentially":[193],"effective":[194],"patients":[197],"sclerosis.":[201]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2007844082","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
